AI Gene Therapy Dose Optimization Engine GeneDose Launches: Calculates Optimal Gene Editing Treatment Plans Based on Individual Genotypes

AI Gene Therapy Dose Optimization Engine GeneDose Launches

On October 29, 2030, gene therapy AI company GeneDose Therapeutics released the GeneDose AI dose optimization engine. The system integrates individual patient genomic data with CRISPR editing efficiency prediction models to automatically calculate gene therapy plans that minimize off-target risk and optimize editing efficiency for each specific patient.

One of the greatest challenges facing CRISPR gene editing therapy is personalized dose optimization — different patients have variations in their genomic sequences, and the same editing plan can have off-target risks and efficiencies that differ by several-fold across patients. GeneDose analyzes a patient's whole-genome data to predict all potential CRISPR guide RNA binding sites in their genome (including off-target sites) and adjusts the dose and guide RNA design accordingly.

The CEO of GeneDose Therapeutics stated: "Traditional gene therapy uses fixed-dose regimens, but individual genomic differences mean the same plan cannot be optimal for all patients. GeneDose brings gene therapy into the era of personalized precision medicine."

In internal validation, GeneDose-optimized plans reduced off-target editing events by an average of 45% while improving editing efficiency at target sites by 18%. The system supports the three mainstream editing tools: CRISPR-Cas9, Cas12a, and base editors.

GeneDose is offered as a SaaS platform, with each optimization costing approximately $5,000. Multiple gene therapy companies have integrated GeneDose into their clinical trial patient stratification workflows.